纤溶酶原激活抑制物,PAI-1英语短句,例句大全

纤溶酶原激活抑制物,PAI-1
1)PAI-1纤溶酶原激活抑制物
1.Objective:To explore the changes of plasma PLG and PAI-1 in type 2 diabetic retinopathy.方法:随机选取2型糖尿病视网膜痛变患者30例,无并发症患者30例,健康人30例,测定血浆纤溶酶原、纤溶酶原激活抑制物,纤溶酶原(PLG)、纤溶酶原激活抑制物(PAI-1)均采用发色底物法检测。

英文短句/例句

1.The relation of plasma plasminogen activator inhibitor activity and coronary heart disease纤溶酶原激活抑制物活性与冠心病发病关系
2.Relationship between plasminogen activator inhibitor 1 and neuroblastoma纤溶酶原激活物抑制物1与神经母细胞瘤
3.Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases纤溶酶原激活物抑制剂-1与心血管疾病
4.Inhibitory effect of green tea polyphenols on plasminogen activator inhibitor-1 expression绿茶多酚对纤溶酶原激活物抑制剂-1表达影响
5.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
6.The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用
7.Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析
8.Change and Implication of PAI-1 in Coronary Heart Disease Patients after Glucose Load冠心病患者糖负荷后纤溶酶原激活物抑制物-1的变化及意义
9.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究
10.Research Progress of Plasminogen Activator Inhibitor One in Gestational Diabetes Mellitus纤溶酶原激活物抑制剂-1（PAI-1）与妊娠期糖尿病的研究
11.Expression of Plasminogen Activator、Plasminogen Activator Inhibitor in Polycystic Ovary Syndrome纤溶酶原激活、抑制因子在PCOS卵巢中的表达
12.Studies on the Thrombin Activatable Fibrinolysis Inhibitor of Coronary Atherosclerotic Heart Disease;冠心病患者凝血酶激活的纤溶抑制物研究
13.The Effect of Amiloride-an Inhibitor of Urokinase on the Pathology of Rat COPD Model;尿激酶型纤溶酶原激活物抑制剂—氨氯吡咪对大鼠COPD模型病理改变的影响
14.The Effect of Astragalus and Safflower Mixture on Expression of Plasminogen Activator Inhibitor 1 in Renal Tubulointerstitial Fibrosis in Rats with Unilateral Ureteral Obstruction;芪红合剂对肾间质纤维化模型大鼠肾组织中纤溶酶原激活物抑制物-1表达的影响
15.Plasma Concentrations of Matrix Metalloproteinase-9 and Plasminogen Activator Inhibitor-1 in Acute Coronary Syndromes;急性冠脉综合征金属蛋白酶-9与纤溶酶原激活物抑制物-1的关系研究
16.Activity of plasma tissue plasminogen activator and plasminogen activator inhibitor in patients with hypertensive disorder complicating pregnancy妊娠期高血压疾病患者血浆组织型纤溶酶原激活物及其抑制物的活性变化
17.The Varity and Mechnisim of the Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes with Hypertriglyceridemia;伴高甘油三酯血症的2型糖尿病纤溶酶原激活物抑制物-1水平变化及机制探讨
18.Influence of Tissue Plasminogen Activator and Its Inhibitors on Neurodegeneration of Spinal Cord after Sciatic Nerve Transection;坐骨神经离断后组织型纤溶酶原激活物及其抑制物对脊髓神经元退变的影响

相关短句/例句

plasminogen activator inhibitor-1纤溶酶原激活物抑制物
1.Objective:To analyze the plasma levels of tissue plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1) in patients with coronary heart disease(CHD) and to assess its clinical implications.方法:回顾性分析本院222例冠心病患者血浆组织型纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制物-1(PAI-1)水平。
2.ObjectiveTo evaluate the plasminogen activator system (plasminogen activator inhibitor-1 and tissue plasminogen activator) in women with PCOS and compared in groups .目的:探讨纤溶酶原激活物抑制物-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的高低与多囊卵巢综合征(polycystic ovary syndrome, PCOS)患者病变发展之间的关系以探寻一较好的监测指标。
3.Objective To investigate the role of rosiglitazone in improving blood lipids and proteinuria in rats with Type 2 diabete,and the effect of rosiglitazone on expressions of plasminogen activator inhibitor-1 in kidney of streptozotocin-diabetic rats.目的研究罗格列酮对2型糖尿病大鼠血糖血脂的影响及肾皮质纤溶酶原激活物抑制物1(PAI-1)表达的作用。
3)plasminogen activator inhibitor纤溶酶原激活物抑制物
1.Objective To observe the influence of Shenluotong on the protein expression of plasminogen activator inhibitor 1(PAI-1) in kidney remaining tissue in rats with kidney failure induced by 5/6 of nephrectomy.目的观察肾络通对5/6肾切除肾衰竭大鼠残余肾组织纤溶酶原激活物抑制物-1(PAI-1)蛋白表达的影响。
2.The activities of tissue plasminogen activator(tPA),plasminogen activator inhibitor(PAI) and plasminogen(PLG) in plasma were determined by chromogenic substrate assay,and thrombi weight was measured.先给大鼠喂药后以FeCl3诱导左侧颈总动脉血栓形成,以发色底物法测定血浆组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物(PAI)和纤溶酶原(PLG)活性,并测定血栓质量。
3.Objective To investigate the changes of serum plasminogen activator inhibitor(PAI),D-dimer and thrombomodulin(TM),and the relationship between these changes and phlegm syndrome or blood-stasis syndrome in patients with acute cerebral infarction.目的探讨急性脑梗死患者血浆纤溶酶原激活物抑制物(PAI)、D-二聚体、血栓调节蛋白(TM)变化与中医痰证、血瘀证变化的关系。
4)Plasminogen activator inhibitor 1纤溶酶原激活物抑制物
1.Objective To study the changes of tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and soluble thrombomodulin (sTM) induced by dengue 2 virus (D 2V) infection of vascular endothelial cells.方法　应用D2 V感染生长良好的第2、3代脐静脉内皮细胞以观察内皮细胞在表达组织纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物1(PAI 1)、凝血酶调节蛋白(TM)等分子变化。
5)plasminogen activator inhibitor纤溶酶原激活物抑制剂
1.Objective To study the effect of Shuxuetong injection on brain microvascular endothelial cell secreting tissue-type plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1).目的研究疏血通注射液对脑微血管内皮细胞(BMECs)分泌组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)的影响。
2.The therapeutic effect and changes of neurofunction deficit score, tissue type plasminogen activator (tPA), plasminogen activator inhibitor (PAI), antithrombin Ⅲ (AT Ⅲ), th.观察两组患者治疗后有效率 ,治疗前后神经功能缺损评分、组织型纤溶酶原激活剂 (tPA)、纤溶酶原激活物抑制剂 (PAI)、抗凝血酶 Ⅲ (AT Ⅲ )、血栓素B2 (TXB2 )及 6 -酮 -前列腺素F1α(6 keto PGF1α)的变化。
3.The plasma tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) activities were determined by chrimogenic substrate method.方法:采用Olimpus-AU5400全自动生化分析仪测定53例SCI患者和55例健康者(对照组)血清Lp(α)水平,用发色底物法检测血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂(PAI)活性,并对SCI患者的血清Lp(α)水平与血浆t-PA和PAI活性进行相关分析。
6)plasminogen activator inhibitor-1纤溶酶原激活物抑制剂
1.AIM:To observe the effects of angiotensin Ⅱ(AngⅡ) on PAI-1 (plasminogen activator inhibitor-1) and tPA (tissue type plasmingen activator) releases in isolated aorta and changes of fibrinolytic function in different states of RAS (renin-angiotensin system) in rats.目的 :观察血管紧张素 (Ang )对大鼠主动脉纤溶酶原激活物抑制剂 (PAI- 1)、组织型纤溶酶原激活物(t PA)活性的影响及不同肾素活性状态下纤溶功能的变化。